Skip to main content

Table 1 Properties of proteasome inhibitors and clinical administration route

From: Proteasome inhibitors as experimental therapeutics of autoimmune diseases

Proteasome inhibitor Class Target(s) Administration route
MG-132 Aldehyde CP and IP Not known
Bortezomib Boronate CP and IP Intravenous/subcutaneous
Carfilzomib (PR-171) α’,β’-Epoxyketone CP and IP Intravenous
Delanzomib (CEP-18770/cephalon) Boronate CP and IP Oral
ONX 0912 (PR-047/oprozomib) α’,β’-Epoxyketone CP and IP Oral
ONX 0914 (PR-957) α’,β’-Epoxyketone IP Intravenous
MLN9708* (ioxazomib): hydrolizes to MLN2238 Boronate CP and IP Oral
Marizomib* (NPI-0052/salinosporamide A) β-Lactone CP and IP Intravenous and oral
PR-924* (IPSI) α’,β’-Epoxyketone IP Intravenous
  1. CP targeting refers primarily to PSMB5 (β5) subunit; IP targeting refers primarily to PSMB8 (β5i) subunit. Asterisks indicate that the compound has not been evaluated for potential anti-inflammatory properties. CP, constitutive proteasome; IP, immunoproteasome; IPSI, immunoproteasome-specific inhibitor.